Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMLX Amylyx Pharmaceuticals

休市中 09-11 16:00:00 EDT

31.62

-0.47

-1.46%

盘后31.62

+0.000.00%

19:51 EDT

最高33.00	最低31.37	成交量171.27万
今开32.09	昨收32.09	日振幅5.08%
总市值39.67亿	流通市值34.63亿	总股本1.25亿
成交额5,473万	换手率1.56%	流通股本1.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":31.62,"timestamp":1789156800000,"preClose":32.09,"halted":0,"volume":1712744,"hourTrading":{"tag":"盘后","latestPrice":31.62,"preClose":31.62,"latestTime":"19:51 EDT","volume":35183,"amount":1112482.568,"timestamp":1789170661087,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.014646307260828993,"floatShares":109507134,"shares":125458283,"eps":-1.430877,"marketStatus":"休市中","change":-0.47,"latestTime":"09-11 16:00:00 EDT","open":32.09,"high":33,"low":31.37,"amount":54726230.00328,"amplitude":0.050795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.430877,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":32.09,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":32.33,"preClose":32.09,"latestTime":"09:29 EDT","volume":334,"amount":10762.628959999998,"timestamp":1789133399999,"change":0.24,"changeRate":0.007479,"amplitude":0.026176},"postHourTrading":{"tag":"盘后","latestPrice":31.62,"preClose":31.62,"latestTime":"19:51 EDT","volume":35183,"amount":1112482.568,"timestamp":1789170661087,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2831826647563334,"impliedVol":0.597,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/AMLX/tweets","defaultTab":"tweets","newsList":[{"id":"1167159559","title":"Amylyx制药与Bachem制造协议：初始五年期限，自动续约三年","url":"https://stock-news.laohu8.com/highlight/detail?id=1167159559","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167159559?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:59","pubTimestamp":1788901183,"startTime":"0","endTime":"0","summary":"Amylyx制药公司与Bachem之间的制造协议设定了初始五年期限。此后，该协议将自动延续三年，除非按照相关条款提前终止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123878767","title":"Amylyx Pharmaceuticals 多肽协议采用固定量定价并设年度调整机制 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1123878767","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123878767?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:59","pubTimestamp":1788901149,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals 与相关方签署的多肽协议，在定价策略上选择了固定量定价模式，同时配套了年度调整机制。这一安排已在提交给美国证券交易委员会（SEC）的文件中详细披露。简而言之，双方约定的价格并非一成不变，而是以固定量为基准，每年动态审视并可能进行调整。这一细节，源自公司最新提交的监管申报材料。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181530912","title":"Amylyx Pharmaceuticals：Bachem与Polypeptide将担任非独家供应商——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1181530912","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181530912?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:56","pubTimestamp":1788900970,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会文件显示，Amylyx Pharmaceuticals已确定Bachem和Polypeptide两家公司为其非独家供应商。这一战略合作安排意味着，Amylyx将不再依赖单一供应渠道，而是通过多元化的供应商网络来保障其药物研发与生产所需的关键原料供应。文件中明确指出，这两家供应商将为Amylyx提供非排他性的供货服务，此举有望增强公司供应链的灵活性与韧性。Amylyx此次的供应商布局调整，或反映了其对公司未来生产需求的审慎规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105644740","title":"Amylyx Pharmaceuticals与Bachem Americas签署制造协议——2026年9月8日SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1105644740","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105644740?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:56","pubTimestamp":1788900969,"startTime":"0","endTime":"0","summary":"2026年9月8日，Amylyx Pharmaceuticals宣布与Bachem Americas达成一项制造合作协议。此项消息源自该公司向美国证券交易委员会提交的公开文件，一经披露便引发行业关注。据悉，此次合作旨在进一步巩固Amylyx在药物生产领域的供应链布局，为其在研及商业化产品提供更稳定的制造支撑。分析人士指出，Amylyx选择在此时引入外部制造伙伴，或暗示其产品商业化进程正加速推进。上述信息已在SEC备案文件中得到确认，标志着Amylyx在运营策略上的又一实质性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535316","title":"Citadel盯上美国页岩油资产！曾竞购WildFire，最终被40亿美元交易“截胡”","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535316","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665535316?lang=zh_cn&edition=full","pubTime":"2026-09-05 00:21","pubTimestamp":1788538872,"startTime":"0","endTime":"0","summary":"城堡投资正瞄准美国原油生产资产，寻求将其在能源领域的实物资产布局进一步扩大。9月4日，据路透援引知情人士，城堡投资近期已与多家私募股权公司接触，寻求收购美国原油生产资产。此前，该机构曾参与竞购WildFire Energy。与此同时，高油价也持续改善油气生产商的盈利能力，多家美国能源企业今年第二季度录得近年来最佳业绩，进一步提升了优质生产资产的吸引力。","market":"sg","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3781106","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Citadel盯上美国页岩油资产！曾竞购WildFire，最终被40亿美元交易“截胡”","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BZmain","CVX","XOMO","BP","XOM","BK4007","TRUN","USOY","SLB","BGR","TOT","XLEX","HAL","XOMX","XLEI","BK4588","CLmain","DVXE","NRGO","MCLmain","BPH","RDS.A","OCTA","OXY","CPE","COP","WEEI","NRGZ","AMLX","GXPE","XOMZ","COMT","SCO","RJN","UCO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331621","title":"市场消息：对冲基金巨头城堡投资（Citadel）拟收购美国页岩油生产资产。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664331621?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:02","pubTimestamp":1788523369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WEEI","GXPE","BK4588","XLEX","BGR","RJN","OCTA","BK4007","AAUM","NRGZ","AMLX","COMT","NRGO","TRUN","DVXE","BK4585","USOY","XLEI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664316243","title":"对冲基金巨头Citadel拟收购美国页岩油生产资产。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664316243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664316243?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:01","pubTimestamp":1788523294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NRGZ","USOY","BK4007","RJN","WEEI","BK4585","AAUM","AMLX","COMT","NRGO","XLEI","BGR","OCTA","TRUN","XLEX","DVXE","GXPE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143797940","title":"Amylyx Pharmaceuticals宣布增发规模达5亿美元的承销公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1143797940","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143797940?lang=zh_cn&edition=full","pubTime":"2026-08-20 11:07","pubTimestamp":1787195228,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布了其增发后的普通股承销公开发行定价，此次发行规模高达5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102263924","title":"Amylyx Pharmaceuticals拟融资，推进Avexitide商业化前期及研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=1102263924","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102263924?lang=zh_cn&edition=full","pubTime":"2026-08-19 04:02","pubTimestamp":1787083332,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布，其融资所得将用于支持Avexitide的商业化前期活动、研发项目以及一般公司用途。此举标志着该公司正积极布局其候选药物的市场推进策略。资金的具体分配计划涵盖多个关键领域，旨在为未来的产品上市奠定坚实基础。通过此举，Amylyx Pharmaceuticals旨在加速其管线资产的开发进程，并强化公司的整体运营能力。这一战略举措反映了公司对Avexitide潜在价值的坚定信心，及其在神经科学领域持续深耕的决心。市场对此消息反应积极，投资者关注公司后续的临床数据及监管进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126658105","title":"Amylyx股价盘前飙升29.7%：关键试验显示其药物显著减少减重手术患者低血糖发作","url":"https://stock-news.laohu8.com/highlight/detail?id=1126658105","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126658105?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:41","pubTimestamp":1787053269,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals盘前交易中股价大幅攀升29.7%。该公司宣布，其研发药物在关键性临床试验中展现出显著疗效——能够有效降低减重手术患者出现低血糖事件的频率。这一利好消息迅速点燃了市场热情，投资者纷纷涌入推动股价走高。试验数据的积极表现，无疑为这家生物制药公司注入了强劲的发展动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151119772","title":"Amylyx Pharmaceuticals：Lucidity 达成全部次要终点，低血糖事件显著减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1151119772","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151119772?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:01","pubTimestamp":1787050911,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals 宣布，其 Lucidity 项目在临床试验中成功触及所有次要终点，并实现了低血糖事件的大幅下降。这一结果，无疑为该公司在代谢疾病领域的布局注入了强劲动力。具体来看，与对照组相比，接受 Lucidity 治疗的患者群体中，低血糖事件的发生率呈现出显著的降低趋势。Amylyx 方面表示，公司正积极准备相关数据，以提交给监管机构审阅，并计划在未来的医学会议上进行详细展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190007899","title":"Amylyx制药：拟于年底向FDA提交Avexitide新药申请，若获批计划2027年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1190007899","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190007899?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:01","pubTimestamp":1787050870,"startTime":"0","endTime":"0","summary":"Amylyx制药公司宣布，计划在年底前向美国食品药品监督管理局（FDA）提交Avexitide的新药申请（NDA）。若该药物获得批准，公司预计将在2027年实现潜在的市场推出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660782436","title":"加拿大石油生产商因油价攀升至多年高位，其套期保值策略遭受损失，目前正效仿美国页岩油企业，尽量不再采用该套保操作。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660782436","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660782436?lang=zh_cn&edition=full","pubTime":"2026-08-17 23:50","pubTimestamp":1786981853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["DBE","BNO","NRGO","BWET","VOOV","DRLL","DBC","SDOG","DUG","BK4570","DVXE","PXE","XLEI","RJN","IXC","VDE","USE","IEO","OILK","GXPE","OCTA","XLEX","NRGZ","DRIP","COMT","WTIU","PEJ","OILU","UGA","TPOR","XOP","GUSH","TRUN","WEEI","FTXN","DIG","ERX","USOI","XES","USL","USOY","XLE","SPXT","AMLX","PXJ","OIH","DBO","UAE","BGR","OILT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409218","title":"恒逸石化：原油价格波动会带动公司产品价格的波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409218","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652409218?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:32","pubTimestamp":1784547120,"startTime":"0","endTime":"0","summary":"证券日报网讯7月20日，恒逸石化在互动平台回答投资者提问时表示，原油价格波动会带动公司产品价格的波动，但公司最终利润取决于各产品价差情况，产品价差及产业链价格的传导受产品自身供求关系、原料供给以及季节性需求等多种因素的影响。东南亚地区成品油供需格局长期偏紧，成品油盈利远好于国内，同时PX、苯等化工产品盈利继续维持高位水平。文莱炼厂继续享受税收、市场化定价以及运保费低廉等优势，并全面把握市场机遇，上半年实现了满产满销，单吨产品盈利长期维持高位水平，成为公司当前及今后业绩增长的核心因素，文莱炼厂的独特区位优势及前瞻战略布局优势愈发凸显。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-20/doc-iniinfqa8229774.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-20/doc-iniinfqa8229774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0208","AIRL","BK0025","BK0028","000703","BK0185","BK0196","BK4588","BK4007","BK0077","AMLX","MDST","AMLP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187382597","title":"Amylyx制药将在Encals 2026大会上公布AMX0114治疗ALS的首个人体剂量探索1期Lumina试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187382597","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187382597?lang=zh_cn&edition=full","pubTime":"2026-06-23 19:00","pubTimestamp":1782212420,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布，将在2026年欧洲肌萎缩侧索硬化症研究大会上，公布其候选药物AMX0114用于治疗ALS的首个人体、剂量探索性1期Lumina试验的研究数据。这项名为Lumina的早期临床试验，旨在评估AMX0114在ALS患者中的安全性、耐受性、药代动力学特征以及初步疗效信号。AMX0114是Amylyx公司研发管线中一款针对神经退行性疾病的新机制疗法。此次在权威的Encals大会上公布初步数据，标志着该药物研发进程中的一个重要里程碑，也为医学界和投资者提供了评估其潜力的关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171717586","title":"Amylyx制药公司宣布AMX0035的2期开放标签Helios试验数据在《临床研究杂志》上经同行评审发表","url":"https://stock-news.laohu8.com/highlight/detail?id=1171717586","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171717586?lang=zh_cn&edition=full","pubTime":"2026-05-16 00:12","pubTimestamp":1778861536,"startTime":"0","endTime":"0","summary":"Amylyx制药公司宣布，其针对AMX0035的2期开放标签Helios试验数据，已在权威医学期刊《临床研究杂志》上经同行评审后正式发表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144099678","title":"Amylyx制药公司宣布针对成人减重手术后低血糖的美国扩大可及计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1144099678","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144099678?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979260,"startTime":"0","endTime":"0","summary":"Amylyx制药公司近日公布了一项针对成人减重手术后低血糖（PBH）患者的美国扩大可及计划（EAP）。该计划旨在为符合条件的PBH成年患者提供其在研药物的获取渠道。\n扩大可及计划通常允许尚未获得正式批准的治疗方案在特定条件下提供给有迫切医疗需求的患者。此举显示了Amylyx公司致力于解决这一罕见且严重代谢紊乱疾病的承诺。\n减重手术后低血糖是一种可能发生在减肥手术后的并发症，其特征是餐后血糖水平异常低下。该计划有望为受此病症困扰的患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153109103","title":"Amylyx制药公司Avexitide三期LUCIDITY试验顶线数据预计2026年第三季度揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1153109103","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153109103?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979235,"startTime":"0","endTime":"0","summary":"Amylyx制药公司宣布，其候选药物Avexitide的关键三期LUCIDITY临床试验的顶线数据结果，预计将于2026年第三季度公布。这项备受关注的试验数据读出，将为评估Avexitide的疗效和安全性提供关键依据。\n此次数据发布将成为衡量该疗法潜力的重要里程碑，对公司的未来发展方向具有决定性意义。投资者和医学界正密切关注这一进展，期待试验结果能为相关疾病治疗带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198448310","title":"Amylyx Pharmaceuticals宣布Avexitide用于减重手术后低血糖症的关键3期LUCIDITY临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1198448310","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198448310?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:01","pubTimestamp":1774350093,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals宣布，其针对Avexitide治疗减重手术后低血糖症（PBH）的关键性3期LUCIDITY临床试验已完成患者入组。该研究的完成标志着药物开发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106700622","title":"Amylyx Pharma 第四季度每股收益$(0.55) 未达到预期$(0.52)","url":"https://stock-news.laohu8.com/highlight/detail?id=1106700622","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106700622?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:14","pubTimestamp":1741086875,"startTime":"0","endTime":"0","summary":"Amylyx Pharma报告季度每股亏损$，低于分析师共识预期的$，低了5.77%。相比去年同期每股收益$0.07，这一结果下降了885.71%。以上内容来自Benzinga Earnings专栏，原文如下：Amylyx Pharma  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 5.77 percent. This is a 885.71 percent decrease over earnings of $0.07 per share from the same period last year.  The company reported $ in sales this quarter. This is a 100.61 percent decrease over sales of $108.45 million the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amylyx Pharma 第四季度每股收益$(0.55) 未达到预期$(0.52)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":-0.0727},{"period":"1month","weight":0.3542},{"period":"3month","weight":1.1672},{"period":"6month","weight":1.2602},{"period":"1year","weight":1.6706},{"period":"ytd","weight":1.6175}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amylyx Pharmaceuticals, Inc.于2014年1月10日根据特拉华州法律成立。该公司是一家临床阶段的制药公司，其使命是为医疗需求未得到满足的社区开发和推进新疗法。该公司在神经退行性疾病和内分泌疾病方面正在进行临床前和临床开发项目。该公司正在推进一项管道，在该管道中，该公司已将研究性疗法与认为这些疗法可以产生最大影响的疾病相匹配，基于明确定义的机制原理、明确的临床结果和生物标志物，以及严格的临床前数据，与模式无关。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.074034},{"month":2,"riseRate":0.6,"avgChangeRate":0.089231},{"month":3,"riseRate":0.2,"avgChangeRate":-0.324118},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019949},{"month":5,"riseRate":0.2,"avgChangeRate":-0.057575},{"month":6,"riseRate":0.8,"avgChangeRate":0.328198},{"month":7,"riseRate":1,"avgChangeRate":0.191259},{"month":8,"riseRate":0.6,"avgChangeRate":0.152419},{"month":9,"riseRate":0.6,"avgChangeRate":0.161945},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.127185}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Amylyx Pharmaceuticals(AMLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Amylyx Pharmaceuticals(AMLX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}